Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments (2016 - 2021)

Historic Short-term Investments for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $454.8 million.

  • Neurocrine Biosciences' Short-term Investments fell 1243.74% to $454.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $454.8 million, marking a year-over-year decrease of 1243.74%. This contributed to the annual value of $613.9 million for FY2020, which is 997.85% up from last year.
  • Neurocrine Biosciences' Short-term Investments amounted to $454.8 million in Q3 2021, which was down 1243.74% from $516.9 million recorded in Q2 2021.
  • Neurocrine Biosciences' Short-term Investments' 5-year high stood at $613.9 million during Q4 2020, with a 5-year trough of $171.5 million in Q1 2017.
  • Over the past 5 years, Neurocrine Biosciences' median Short-term Investments value was $479.0 million (recorded in 2019), while the average stood at $431.8 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Short-term Investments tumbled by 3558.3% in 2017, and later skyrocketed by 9493.33% in 2018.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Short-term Investments stood at $261.2 million in 2017, then surged by 94.93% to $509.2 million in 2018, then rose by 9.62% to $558.2 million in 2019, then increased by 9.98% to $613.9 million in 2020, then dropped by 25.92% to $454.8 million in 2021.
  • Its Short-term Investments was $454.8 million in Q3 2021, compared to $516.9 million in Q2 2021 and $521.1 million in Q1 2021.